エンドトキシン研究9　自然免疫の最前線

出版社： 医学図書出版
著者：
発行日： 2006-12-10
分野： 基礎・関連科学  >  生物/分子生物
ISBN： 4871513416
電子書籍版： 2006-12-10 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

4,400 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,200 円(税込)

購入する

商品紹介

第11回日本エンドトキシン研究会の講演内容をまとめた「エンドトキシン研究9」発刊となりました。

目次

  • エンドトキシン研究9　自然免疫の最前線

    ―目次―

    第1章　特別講演
    第2章　シンポジウム1「Toll-like receptorによる病原体認識と
    　　　　シグナル伝達機構」
    第3章　シンポジウム2「自然免疫の細胞群と疾患」
    第4章　一般演題

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

P.7 掲載の参考文献
1) Ulevitch RJ & Tobias PS : Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13 : 437-457, 1995
PubMed
2) Akashi S, Saitoh S, Wakabayashi Y, et al. : Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2 : higher affinity than that with MD-2 or CD 14. J Exp Med 198 : 1035-1042, 2003
PubMed
3) Saitoh S, Akashi S, Yamada T, et al. : Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR 4) -MD-2 and ligand-induced TLR 4 oligomerization. Int Immunol 16 : 961-969, 2004
 
4) Kobayashi M, Saitoh S, Tanimura N, et al. : Regulatory Roles for MD-2 and TLR 4 in Ligand-Induced Receptor Clustering. J Immunol 176 : 6211-6218, 2006
 
5) Akira S, Uematsu S, Takeuchi O : Pathogen recognition and innate immunity. Cell 124 : 783-801, 2006
PubMed
6) Pugin J, Heumann ID, Tomasz A, et al. : CD 14 is a pattern recognition receptor. Immunity 1 : 509-516, 1994
 
7) Lee HK, Dunzendorfer S, Soldau K, et al. : Double-stranded RNA-mediated TLR 3 activation is enhanced by CD 14. Immunity 24 : 153-163, 2006
 
8) Compton T, Kurt-Johnes EA, Boehme KW, et al. : Human cytomegalovirus activates inflammatory cytokine responses via CD 14 and Toll-like receptor 2. J Virol 77 : 4588-4596, 2003
 
9) Kurt-Jones EA, Popova L, Kwinn L, et al. : Pattern recognition receptors TLR 4 and CD 14 mediate response to respiratory syncytial virus. Nat Immunol 1 : 398-401, 2000
 
10) Pauligk C, Nain M, Reiling N, et al. : CD 14 is required for influenza A virus-induced cytokine and chemokine production. Immunobiology 209 : 3-10, 2004
 
11) Shuto T, Kato K, Mori Y, et al. : Membraneanchored CD 14 is required for LPS-induced TLR 4 endocytosis in TLR 4/MD-2/CD 14 overexpressing CHO cells. Biochem Biophys Res Commun. 1402-1409, 2005
 
12) Dunzendorfer S, Lee HK, Soldau K, et al. : TLR 4 is the signaling but not the lipopolysac charide uptake receptor. J Immunol 173 : 1166-1170, 2004
 
13) Jiang Z, Georgel P, Du X, et al. : CD 14 is required for MyD 88-independent LPS signaling. Nat Immunol 6 : 565-570, 2005
 
14) Husebye H, Halaas O, Stenmark H, et al. : Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. EMBO J 25 : 683-692, 2006
PubMed
P.16 掲載の参考文献
1) Martinon F, Tschopp J : Inflammatory caspases : linking an intracellular innate immune system to autoinflammatory diseases. Cell 117 : 561-574, 2004
PubMed
2) Yoneyama M, Kikuchi M, Natsukawa T, et al. : The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunor 5 : 730-737, 2004
 
3) Mariathasan S, Weiss DS, Newton K, et al. : Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440 : 228-232, 2006
PubMed
4) Kanneganti TD, Ozoren N, Body-Malapel M, et al. : Bacterial RNA and small antiviral compounds activate caspase -1 through cryopyrin/Nalp 3. Nature 440 : 233-236, 2006
 
5) Martinon F, Petrilli V, Mayor A, et al. : Gout-associated uric acid crystals activate the NALP 3 inflammasome. Nature 440 : 237-241, 2006
 
6) Akira S, Takeda K : Toll-like receptor signalling. Nat Rev Immunol 4 : 499-511, 2004
PubMed
7) Miyake K : Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol 12 : 186-192, 2004
PubMed
8) Seong SY, Matzinger P : Hydrophobicity : an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4 : 469-478, 2004
PubMed
9) Ichijo H, Nishida E, Irie K, et al. : Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p 38 signaling pathways. Science 275 : 90-94, 1997
 
10) Matsuzawa A, Nishitoh H, Tobiume K, et al. : Physiological roles of ASK1-mediated signal transduction in oxidative stress- and endo-plasmic reticulum stress-induced apoptosis : advanced findings from ASK1 knockout mice. Antioxid Redox Signal 4 : 415-425, 2002
 
11) Matsuzawa A, Saegusa K, Noguchi T, et al. : ROS-dependent activation of the TRAF 6-ASK1-p 38 pathway is selectively required for TLR 4-mediated innate immunity. Nat Immunol 6 : 587-592, 2005
 
12) Su B : Linking stress to immunity? Nat Immunol 6 : 541-542, 2005
PubMed
13) Kyriakis JM, Avruch J : Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81 : 807-869, 2001
PubMed
14) Saitoh M, Nishitoh H, Fujii M, et al. : Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17 : 2596-2606, 1998
PubMed
15) Nishitoh H, Saitoh M, Mochida Y, et al. : ASK1 is essential for JNK/SAPK activation by TRAF 2. Mol Cell 2 : 389-395, 1998
PubMed
16) Tobiume K, Matsuzawa A, Takahashi T, et al. : ASK1 is required for sustained activations of JNK/p 38 MAP kinases and apoptosis. EMBO Rep 2 : 222-228, 2001
 
17) Kadowaki H, Nishitoh H, Urano F, et al. : Amyloid β induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ 12 : 19-24, 2005
 
18) Izumiya Y, Kim S, Izumi Y, et al. : Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. Circ Res 93 : 874-883, 2003
 
19) Nishitoh H, Matsuzawa A, Tobiume K, et al. : ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev 16 : 1345-1355, 2002
PubMed
20) Takeda K, Matsuzawa A, Nishitoh H, et al. : Involvement of ASK1 in Ca 2+ -induced p 38 MAP kinase activation. EMBO Rep 5 : 161-166, 2004
 
21) Matsuzawa A, Ichijo H : Stress-responsive protein kinases in redox-regulated apoptosis signaling. Antioxid Redox Signal 7 : 472-481, 2005
PubMed
22) Ulevitch RJ : Therapeutics targeting the innate immune system. Nat Rev Immunol 4 : 512-520, 2004
PubMed
23) Kim DH, Feinbaum R, Alloing G, et al. : A conserved p38 MAP kinase pathway in Caenorhabditis elegans innate immunity. Science 297 : 623-626, 2002
PubMed
24) Noguchi T, Takeda K, Matsuzawa A, et al. : Recruitment of tumor necrosis factor receptorassociated factor family proteins to apoptosis signal-regulating kinase 1 signalosome is essential for oxidative stress-induced cell death. J Biol Chem 280 : 37033-37040, 2005
PubMed
25) Hsu HY, Wen MH : Lipopolysaccharidemediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J Biol Chem 277 : 22131-22139, 2002
PubMed
26) Lehner MD, Schwoebel F, Kotlyarov A, et al. : Mitogen-activated protein kinase-activated protein kinase 2-deficient mice show increased susceptibility to Listeria monocytogenes infection. J Immunol 168 : 4667-4673, 2002
PubMed
27) Blander JM, Medzhitov R : Regulation of phagosome maturation by signals from toll-like receptors. Science 304 : 1014-1018, 2004
PubMed
28) Trinchieri G : Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3 : 133-146, 2003
PubMed
29) Swanson J : The pick of the nibbled bits. Nature 440 : 750-751, 2006
PubMed
30) Blander JM, Medzhitov R : Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440 : 808-812, 2006
PubMed
P.24 掲載の参考文献
1) Janeway CA, Jr. : Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54 Pt 1 : 1-13, 1989
 
2) Medzhitov R, Janeway CA, Jr. : Innate immunity : the virtues of a nonclonal system of recognition. Cell 91 : 295-298, 1997
PubMed
3) Medzhitov R, Janeway CA, Jr. : Innate immune induction of the adaptive immune response. Cold Spring Harb Symp Quant Biol 64 : 429-435, 1999
PubMed
4) Ulevitch RJ, Tobias PS : Recognition of gramnegative bacteria and endotoxin by the innate immune system. Curr Opin Immunol 11 : 19-22, 1999
 
5) Yamazaki S, Muta T, Takeshige K : A novel IκB protein, 1κB-ζ, induced by proinflammatory stimuli, negatively regulates nuclear factor-κB in the nuclei. J Biol Chem 276 : 27657-27662, 2001
 
6) Kitamura H, Kanehira K, Okita K, et al. : MAIL, a novel nuclear IκB protein that potentiates LPS-induced IL-6 production. FEBS Lett 485 : 53-56, 2000
 
7) Haruta H, Kato A, Todokoro K : Isolation of a novel interleukin-1-inducible nuclear protein bearing ankyrin-repeat motifs. J Biol Chem 276 : 12485-12488, 2001
PubMed
8) Ohno H, Takimoto G, McKeithan TW : The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 60 : 991-997, 1990
PubMed
9) Fiorini E, Schmitz I, Marissen WE, et al. : Peptide-induced negative selection of thymocytes activates transcription of an NF-κB inhibitor. Mol Cell 9 : 637-648, 2002
 
10) Shiina T, Morimatsu M, Kitamura H, et al. : Genomic organization, chromosomal localization, and promoter analysis of the mouse Mail gene. Immunogenetics 53 : 649-655, 2001
PubMed
11) Motoyama M, Yamazaki S, Eto-Kimura A, et al. : Positive and negative regulation of nuclear factor-κB-mediated transcription by IκB-ζ, an inducible nuclear protein. J Biol Chem 280 : 7444-7451, 2005
 
12) Yamazaki S, Muta T, Matsuo S, et al. : Stimulus-specific induction of a novel nuclear fac tor-κB regulator, IκB-ζ, via Toll/Interleukin-1 receptor is mediated by mRNA stabilization. J Biol Chem 280 : 1678-1687, 2005
 
13) Yamamoto M, Yamazaki S, Uematsu S, et al, : Regulation of Toll/IL-1-receptormediated gene expression by the inducible nuclear protein IκBζ. Nature 430 : 218-222, 2004
 
14) Wulczyn FG, Naumann M, Scheidereit C : Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-κB. Nature 358 : 597-599, 1992
 
15) Hirotani T, Lee PY, Kuwata H, et al. : The nuclear IκB protein IκBNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria. J Immunol 174 : 3650-3657, 2005
 
16) Shiina T, Konno A, Oonuma T, et al. : Targeted disruption of MAIL, a nuclear IκB protein, leads to severe atopic dermatitis-like disease. J Biol Chem 279 : 55493-55498, 2004
 
17) Ueta M, Hamuro J, Yamamoto M, et al. : Spontaneous ocular surface inflammation and goblet cell disappearance in IκBζ genedisrupted mice. Invest Ophthalmol Vis Sci 46 : 579-588, 2005
 
18) Kuwata H, Matsumoto M, Atarashi K, et al. : IκBNS inhibits induction of a subset of Toll-like receptor-dependent genes and limits inflammation. Immunity 24 : 41-51, 2006
 
19) Eto A, Muta T, Yamazaki S, et al. : Essential roles for NF-κB and a Toll/IL-1 receptor domain-specific signal (s) in the induction of IκB一ζ. Biochem Biophys Res Commun 301 : 495-501, 2003
 
20) Yamamoto M, Takeda K, Akira S : TIR domain-containing adaptors define the specificity of TLR signaling. Mol Immunol 40 : 861-868, 2004
PubMed
21) Ninomiya-Tsuji J, Kishimoto K, Hiyama A, et al. : The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398 : 252-256, 1999
 
22) Wang C, Deng L, Hong M, et al. : TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412 : 346-351, 2001
 
23) Irie T, Muta T, Takeshige K : TAK1 mediates an activation signal from toll-like receptor (s) to nuclear factor-κB in lipopolysaccharide-stimulated macrophages. FEBS Lett 467 : 160-164, 2000
 
24) Wallach D, Varfolomeev EE, Malinin NL, et al. : Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17 : 331-367, 1999
PubMed
25) Ito T, Morimatsu M, Oonuma T, et al. : Transcriptional regulation of the MAIL gene in LPS-stimulated RAW 264 mouse macrophages. Gene 342 : 137-143, 2004
 
P.39 掲載の参考文献
1) Taniguchi T, Ogasawara K, Takaoka A, et al. : IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19 : 623-655, 2001
 
2) Akira S, Uematsu S & Takeuchi O. Pathogen recognition and innate immunity. Cell 124 : 783-801, 2006
PubMed
3) Sato M, Suemori H, Hata N, et al. : Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 13 : 539-548, 2000
PubMed
4) Takaoka A, Yanai H : Interferon signalling network in innate defence. Cell Microbiol 8 : 907-922, 2006
PubMed
5) Hoshino K, Sugiyama T, Matsumoto M, et al. : IκB kinase-α is critical for interferon-α production induced by Toll-like receptors 7 and 9. Nature 440 : 949-953, 2006
 
6) Uematsu S, Sato S, Yamamoto M, et al. : Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR) 7-and TLR 9-mediated interferon-｛alpha｝induction. J Exp Med 201 : 915-923, 2005
PubMed
7) Liu YJ. IPC : professional type 1 interferonproducing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23 : 275-306, 2005
PubMed
8) Honda K, Yanai H, Negishi H, et al. : IRF-7 is the master regulator of type-I interferondependent immune responses. Nature 434 : 772-777, 2005
PubMed
9) Honda K, Ohba Y, Yanai H, et al. : Spatiotemporal regulation of MyD 88-IRF-7 signalling for robust type-I interferon induction. Nature 434 : 1035-1040, 2005
 
10) Takaoka A, Yanai H, Kondo S, et al. : Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434 : 243-249, 2005
PubMed
11) Leung TH, Hoffmann A, Baltimore D : One ucleotide in aκB site can determine cofactor specificity for NF-κB dimers. Cell 118 : 453-464, 2004
 
12) Ogawa S, Lozach J, Benner C, et al. : Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122 : 707-721, 2005
PubMed
13) Wietek C, Miggin SM, Jefferies CA, et al. : Interferon regulatory factor-3-mediated activation of the interferon-sensitive response element by Toll-like receptor (TLR) 4 but not TLR 3 requires the p 65 subunit of NF-κB. J Biol Chem 278 : 50923-50931, 2003
 
14) Barnes B, Lubyova B, Pitha PM : On the role of IRF in host defense. J Interferon Cytokine Res 22 : 59-71, 2002
PubMed
15) Lohoff M, Mak TW : Roles of interferonregulatory factors in T-helper-cell differentiation. Nat Rev Immunol 5 : 125-135, 2005
 
16) Yamagata T, Nishida J, Tanaka S, et al. : A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferonregulated genes. Mol Cell Biol 16 : 1283-1294, 1996
 
17) Mittrucker HW, Matsuyama T, Grossman A, et al. : Requirement for the transcription factor LSIRF/IRF 4 for mature B and T lymphocyte function. Science 275 : 540-543, 1997
 
18) Honda K, Yanai H, Mizutani T, et al. : Role of a transductional-transcriptional processor complex involving MyD 88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci USA 101 : 15416-15421, 2004
 
19) Negishi H, Ohba Y, Yanai H, et al. : Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci USA 102 : 15989-15994, 2005
PubMed
20) Ghosh S, May MJ, Kopp EB : NF-kappa B and Rel proteins : evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16 : 225-260, 1998
PubMed
21) Honma K, Udono H, Kohno T, et al. : Interferon regulatory factor 4 negatively regulates the production of proinflammatory cytokines by macrophages in response to LPS. Proc Natl Acad Sci USA 102 : 16001-16006, 2005
PubMed
22) Ogawa S, Lozach J, Benner C, et al. : Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122 : 707-721, 2005
PubMed
23) Moore PS, Chang Y : Kaposi's sarcoma-associated herpesvirus immunoevasion and tumorigenesis : two sides of the same coin? Annu Rev Microbiol 57 : 609-639, 2003
PubMed
24) Loo YM, Owen DM, Li K, et al. : Viral and therapeutic control of IFN-β promoter stimulator l during hepatitis C virus infection. Proc Natl Acad Sci USA 103 : 6001-6006, 2006
 
25) Li K, Foy E, Ferreon JC, et al. : Immune evasion by hepatitis C virus NS 3/4 A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 102 : 2992-2997, 2005
 
26) Andrejeva J, Childs KS, Young DF, et al. : The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proc Natl Acad Sci USA 101 : 17264-17269, 2004
 
27) Yoneyama M, Kikuchi M, Natsukawa T, et al. : The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5 : 730-737, 2004
PubMed
28) Kato H, Sato S, Yoneyama M, et al. : Cell type-specific involvement of RIG-I in antiviral response. Immunity 23 : 19-28, 2005
 
29) Kato H, Takeuchi O, Sato S, et al. : Differential roles of MDA 5 and RIG-I helicases in the recognition of RNA viruses. Nature 441 : 101-105, 2006
 
30) Ishii KJ, Coban C, Kato H, et al. : A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol 7 : 40-48, 2006
PubMed
31) Stetson DB, Medzhitov R : Recognition of cytosolic DNA activates an IRF 3-dependent innate immune response. Immunity 24 : 93-103, 2006
 
32) Kariko K, Ni H, Capodici J, et al. : mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 279 : 12542-12550, 2004
PubMed
33) Graham RR, Kozyrev SV, Baechler EC, et al. : A common haplotype of interferon regulatory factor 5 (IRF 5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38 : 550-555, 2006
 
34) Negishi H, Fujita Y, Yanai H, et al. : Evidence for licensing of IFN-γ-induced IFN regulatory factor 1 trenscription factor by MyD 88 in Tol1-like receptor-dependent gene induction program. Proc Nat 1 Acad Sci USA 103 : 15136-15141, 2006
 
35) Saitoh T, Tun-Kyi A, Ryo A, et al. : Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pinl. Nat Immunol 7 : 598-605, 2006
 
P.48 掲載の参考文献
1) Wysocka M, Kubin M, Vieira LQ, et al. : Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharideinduced shock in mice. Eur J Immunol 25 : 672-676, 1995
 
2) Takada H, Galanos C : Enhancement of endotoxin lethality and generation of anaphylactoid reactions by lipopolysaccharides in muramyl-dipeptide-treated mice. Infect Immun 55 : 409-413, 1987
PubMed
3) Galanos C, Freudenberg MA, Retter W : Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 76 : 5939-5943, 1979
 
4) Lehmann V, Freudenberg MA, Galanos C : Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and Dgalactosaminetreated mice. J Exp Med 165 : 657-663, 1987
PubMed
5) Silverstein R : D-galactosamine lethality model : scope and limitations. J Endotoxin Res 10 : 147-162, 2004
PubMed
6) Yu KO, Porcelli SA : The diverse functions of CD 1 d-restricted NKT cells and their potential for immunotherapy. Immunol Lett 100 : 42-55, 2005
 
7) Kobayashi E, Motoki K, Uchida T, et al. : KRN 7000, a novel immunomodulator, and its antitumor activities. Oncol Res 7 : 529-534, 1995
PubMed
8) Kawano T, Cui J, Koezuka Y, et al. : Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc Natl Acad Sci U S A 95 : 5690-5693, 1998
 
9) Giaccone G, Punt CJ, Ando Y, et al. : A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN 7000) in patients with solid tumors. Clin Cancer Res 8 : 3702-3709, 2002
 
10) Miellot A, Zhu R, Diem S, et al. : Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Eur J Immunol 35 : 3704-3713, 2005
 
11) Singh AK, Yang JQ, Parekh VV, et al. : The natural killer T cell ligand α-galactosylceramide prevents or promotes pristane-induced lupus in mice. Eur J Immunol 35 : 1143-1154, 2005
 
12) Sharif S, Arreaza GA, Zucker P, et al. : Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 7 : 1057-1062, 2001
 
13) Minagawa S, Ohyama C, Hatakeyama S, et al. : Activation of natural killer T cells by α-galactosylceramide mediates clearance of acteria in murlne urinary tract infection. J Urol 173 : 2171-2174, 2005
 
14) Chackerian A, Alt J, Perera V, et al. : Activation of NKT cells protects mice from tuberculosis. Infect Immun 70 : 6302-6309, 2002
PubMed
15) Nieuwenhuis EE, Matsumoto T, Exley M, et al. : CD 1 d-dependent macrophage-mediated clearance of Pseudomonas aeraginosa from lung. Nat Med 8 : 588-593, 2002
 
16) Zhou D, Mattner J, Cantu C, et al. : Lysosomal glycosphingolipid recognition by NKT cells. Science 306 : 1786-1789, 2004
PubMed
17) Wu D, Xing GW, Poles MA, et al. : Bacterial glycolipids and analogs as antigens for CD 1 drestricted NKT cells. Proc Natl Acad Sci U S A 102 : 1351-1356, 2005
 
18) Kinjo Y, Wu D, Kim G, et al. : Recognition of bacterial glycosphingolipids by natural killer Tcells. Nature 434 : 520-525, 2005
PubMed
19) Mattner J, Debord KL, Ismail N, et al : Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434 : 525-529, 2005
PubMed
20) Nakagawa R, Nagafune I, Tazunoki Y, et al. : Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α-galactosylceramide in mice. J Immunol 166 : 6578-6584, 2001
 
P.56 掲載の参考文献
1) Akagawa KS, Maruyama Y, Takano M, et al. : A cell surface antigen expressed on mouse lung macrophages. Microbiol Immunol 25 : 1215-1220, 1981
 
2) Akagawa KS, Tokunaga T : Lack of binding of bacterial lipopolysaccharide to mouse lung macrophages and restoration of binding by gamma interferon. J Exp Med 162 : 1444-1459, 1985
PubMed
3) Akagawa KS, Kamoshita K, Tokunaga T : Effects of granulocyte-macrophage colonystimulating factor and colony-stimulating factor-1 on the proliferation and differentiation of murine alveolar macrophages. J Immunol 141 : 3383-3390, 1988
PubMed
4) Pixley FJ, Stanley ER : CSF-1 regulation of the wandering macrophage : complexity in action. Trends Cell Biol 14 : 628-638, 2004
PubMed
5) Kamada N, Hisamatsu T, Okamoto S, et al. : Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J Immunol 175 : 6900-6908, 2005
PubMed
6) Nakata K, Akagawa KS, Fukayama M, et al. : Granulocyte-macrophage colony-stimulating factor promotes the proliferation of human alveolar macrophages in vitro. J Immunol 147 : 1266-1272, 1991
PubMed
7) Uchida K, Nakata K, Trapnell BC, et al. : High-aflinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 103 : 1089-1098, 2004
 
8) Kawasaki K, Gomi K, Nishijima M : Cutting edge : Gln 22 of mouse MD-2 is essential for species-specific lipopolysaccharide mimetic action of taxol. J Immunol 166 : 11-14, 2001
PubMed
9) Liu PT, Stenger S, Li H, et al. : Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311 : 1770-1773, 2006
PubMed
10) Akagawa KS : Functional heterogeneity of colony-stimulating factor-induced human monocyte-derived macrophages. Int J Hematol. 76 : 27-34, 2002
PubMed
11) Mochida-Nishimura K, Akagawa KS, Rich EA : Interleukin-10 contributes development of macrophage suppressor activities by macrophage colony-stimulating factor, but not by granulocyte-macrophage colony-stimulating factor. Cell Immunol 214 : 81-88, 2001
 
12) Verreck FA, de Boer T, Langenberg DM, et al. : Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco) bacteria. Proc Natl Acad Sci U S A 101 : 4560-4565, 2004
PubMed
13) Komuro I, Keicho N, Iwamoto A, et al. : Human alveolar macrophages and granulocyte-macrophage colony-stimulating factor-induced monocyte-derived macrophages are resistant to H2O2 via their high basal and inducible levels of catalase activity. J Biol Chem 276 : 24360-24364, 2001
PubMed
14) Komuro I, Yasuda T, Iwamoto A, et al. : Catalase plays a critical role in the CSF-independent survival of human macrophages via regulation of the expression of BCL-2 family. J Biol Chem 280 : 41137-41145, 2005
 
15) Komuro I, Yokota Y, Yasuda S, et al. : CSF-induced and HIV-1-mediated distinct regulation of Hck and C/EBPbeta represent a heterogeneous susceptibility of monocyte-derived macrophages to M-tropic HIV-1 infection. J Exp Med 198 : 443-453, 2003
 
16) Hashimoto S, Yamada M, Motoyoshi K, et al. : Enhancement of macrophage colonystimulating factor-induced growth and differentiation of human monocytes by interleukin-10. Blood 89 : 315-321, 1997
PubMed
17) Mocellin S, Panelli MC, Wang E, et al. : The dual role of IL-10. Trends Immunol 24 : 36-43, 2003
PubMed
18) Hashimoto SI, Komuro I, Yamada M, et al. : IL-1 oinhibits granulocyte-macrophage colonystimulating factor-dependent human monocyte survival at the early stage of the culture and inhibits the generation of macrophages. J Immunol 167 : 3619-3625, 2001
 
19) Akagawa KS, Takasuka N, Nozaki Y, et al. : Generation of CD1 RelB+ dendritic cells and tartrate-resistant acid phosphatase-positive osteoclast-like multinucleated giant cells from human monocytes. Blood 88 : 4029-4039, 1996
PubMed
20) Gordon S, Taylor PR : Monocyte and macro phage heterogeneity. Nat Rev Immunol 5 : 953-964, 2005
 
21) Randolph GJ, Sanchez-Schmitz G, Liebman RM, et al. : The CD 16 (+) (FcgammaRIII (+)) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med 196 : 517-527, 2002
 
22) Geissmann F, Jung S, Littman DR : Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19 : 71-82, 2003
 
P.62 掲載の参考文献
1) Adelakun A, Schwartz E, Blais L : Occupational heat exposure. Appl Occup Environ Hyg Mar 14 : 153-154, 1999
PubMed
2) Easterling DR, Meehl GA, Parmesan C, et al. : Climate extremes : observations, modeling, and impacts. Science 298 : 2068-2074, 2000
 
3) Poumadere M, Mays C, Le Mer S, et al. : The 2003 heat wave in France : dangerous climate change here and now. Risk Anal 25 : 1483-1494, 2005
PubMed
4) Hall DM, Buettner GR, Oberley LW, et al. : Mechanisms of circulatory and intestinal barrier dysfunction during whole body hyperthermia. Am J physiol Heart Circ Physiol 280 : H509-H521, 2001
PubMed
5) Buono MJ, Sj oholm NT : Effect of physical training on peripheral sweat production. J Appl Physiol 65 : 811-814, 1988
 
6) Deschamps A, Levy RD, Cosio MG, et al. : Effect of saline infusion on body temperature and endurance during heavy exercise. J Appl Physiol 66 : 2799-2804, 1989
PubMed
7) Bouchama A, Knochel Jp : Heat stroke. N Engl J Med 346 : 1978-1988, 2002
PubMed
8) Gabay C, Kushner I : Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 : 448-454, 1999 [Erratum, N Engl J Med 340 : 1376, 1999］
 
9) Bouchama A, Parhar RS, el-Yazigi A, et al. : Endotoxemia and release of tumor necrosis factor and interleukin 1 alpha in acute heat-stroke. J Appl Physiol 70 : 2640-2644, 1991
 
10) Cannon JG, Kluger MJ : Endogenous pyrogen activity in human plasma after exercise. Science 220 : 617-619, 1983
PubMed
11) Pedersen BK, Hoffman-Goetz L : Exercise and the immune system : regulation, integration, and adaptation. Physiol Rev 80 : 1055-1081, 2000
PubMed
12) Sakurada S, Hales JR : A role for gastrointestinal endotoxins in enhancement of heat tolerance by physical fitness. J Appl Physiol 84 : 207-214, 1998
PubMed
13) 藤島史喜, 藤原英紀, 寺島徹, 他 : 熱中症に合併した盲腸壊死の一例 日本臨床外科学会雑誌 62 : 1326, 2001
 
14) 立川弘孝, 芦田孔, 松原欣也, 他 : Bacterial translocationにより急速に病状が悪化した熱射病の1剖検例 京都市立病院紀要 20 : 54-59, 2000
 
15) Ostrowski K, Rohde T, Zacho M, et al. : Evidence that interleukin-6 is produced in human skeletal muscle during prolonged runing. J Physiol 508 : 949-953, 1998
 
16) Moseley PL : Heat shock proteins and heat adaptation of the whole organism. J Appl Physiol 83 : 1413-1417, 1997
PubMed
17) Riabowol KT, Mizzen LA, Welch WJ : Heat shock is lethal to fibroblasts microinjected with antibodies against hsp 70. Science 242 : 433-436, 1988
PubMed
P.68 掲載の参考文献
1) Ulloa L, Ochani M, Yang H, et al. : Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci U S A. 99 : 12351-12356, 2002
PubMed
2) Beutler B, Milsark IW, Cerami AC : Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229 : 869-871, 1985
 
3) Wang H, Bloom O, Zhang M, et al. : HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 : 248-251, 1999
PubMed
4) Polderman KH, Armand RJ Girbes : Drug intervention trials in sepsis : divergent results Lancet 363 : 1721-1723, 2004
 
5) Sessler CN : Steroids for Septic Shock Back From the Dead? (Con) CHEST 123 : 482S-489S, 2003
PubMed
6) Beutler B, Krochin N, Milsark IW, et al. : Control of cachectin (tumor necrosis factor) synthesis : mechanisms of endotoxin resistance. Science 232 : 977-980, 1986
PubMed
7) Singer M, Santis VD, Vitale D, et al. : Multiorgan failure is an adaptive, endocrinemediated, metabolic response to overwhelming systemic inflammation. Lancet 364 : 545-548, 2004
 
8) Hotchkiss RS, Karl IE : The Pathophysiology and Treatment of Sepsis N Engl J Med 348 : 138-150, 2003
PubMed
9) Brealey D, Brand M, Hargreaves I, et al. : Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360 : 219-223, 2002
PubMed
10) Han Y, Englert JA, Yang R, et al. : Ethyl pyruvate inhibits nuclear factor-kappaB dependent signaling by directly targeting p 65. Related Articles, J Pharmacol Exp Ther 312 : 1097-1105, 2005
 
11) Song M, Kellum JA, Kaldas H, et al. : Evidence that glutathione depletion is a mechanism responsible for the anti-inflammatory effects of ethyl pyruvate in cultured lipopolysaccharide-stimulated RAW 264. 7 cells. J Pharmacol Exp Ther 308 : 307-316, 2004
PubMed
12) Martin E, Rosenthal RE, Fiskum G : Pyruvate Dehydrogenase Complex : Metabolic Link to Ischemic Brain Injury and Target of Oxidative Stress. Journal of Neuroscience Research 79 : 240-247, 2005
PubMed
13) Mulier KE, Beilman GJ, Conroy MJ, et al. : Ringer's ethyl pyruvate in hemorrhagic shock and resuscitation does not improve early hemodynamics or tissue energetics. Shock 23 : 248-252, 2005
PubMed
14) Spagnoli A, Lucca U, Menasce G, et al. : Longterm acetyl-L-carnitine treatment in Alzheimer's disease. Neurology 41 : 1726-1732, 1991
PubMed
15) Rai G, Wright G, Scott L, et al. : Double-blind, placebo controlled study of acetyl-1-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin 11 : 638-647, 1990
PubMed
16) Tempesta E, Casella L, Pirrongelli C, et al. : L-acetylcarnitine in depressed elderly subjects. A cross-over study vs placebo. Drugs Exp Clin Res 13 : 417-423, 1987
PubMed
17) Onofrj M, Fulgente T, Melchionda D, et al. : Lacetylcarnitine as a new therapeutic approach for peripheralneuropathies with pain. Int J CIin Pharm Res 15 : 9-15, 1995
 
18) Lowitt S, Malone JI, Salem AF, et al. : Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 44 : 677-680, 1995
PubMed
P.74 掲載の参考文献
1) Riedemann NC, Guo RF, Ward PA : The enigma of sepsis. J CIin Invest 112 : 460-467, 2003
 
2) Macdonald J, Galley HF, Webster NR : Oxidative stress and gene expression in sepsis. Br J Anaesth 90 : 221-232, 2003
PubMed
3) Rotstein OD : Antioxidant therapy in critical illness. Crit Care Med 32 : 610-611, 2004
PubMed
4) Takahashi T, Morita K, Akagi R, et al. : Heme oxygenase-1 : a novel therapeutic target in oxidative tissue injuries. Curr Med Chem 11 : 1545-1561, 2004
PubMed
5) Poss KD, Tonegawa S : Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci U S A 94 : 10925-10930, 1997
PubMed
6) Yachie A, Niida Y, Wada T, et al. : Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 103 : 129-135, 1999
PubMed
7) Suzuki T, Takahashi T, Yamasaki A, et al. : Tissue-specific gene expression of heme oxygenase-1 (HO-1) and non-specific deltaaminolevulinate synthase (ALAS-N) in a rat model of septic multiple organ dysfunction syndrome. Biochem Pharmacol 60 : 275-283, 2000
 
8) Fujii H, Takahashi T, Nakahira K, et al. : Protective role of heme oxygenase-1 in the intestinal tissue injury in an experimental model of sepsis. Crit Care Med 31 : 893-902, 2003
 
9) Uehara K, Takahashi T, Fujii H, et al. : The lower intestinal tract-specific induction of heme oxygenase-1 by glutamine protects against endotoxemic intestinal injury. Crit Care Med 33 : 381-390, 2005
PubMed
10) Bissell DM, Hammaker LE : Cytochrome P-450 heme and the regulation of hepatic heme oxygenase activity. Arch Biochem Biophys 176 : 91-102, 1976
PubMed
11) Igarashi K, Sun J : The heme-Bach 1 pathway in the regulation of oxidative stress response and erythroid differentiation. Antioxid Redox Signal 8 : 107-118, 2006
 
12) Fink MP : Gastrointestinal mucosal injury in experimental models of shock, trauma, and sepsis. Crit Care Med 19 : 627-641, 1991
 
13) Chung SW, Chen YH, Yet SF, et al. : Endotoxin-induced down-regulation of Elk-3 facilitates heme oxygenase-1 induction in macrophages. J Immunol 176 : 2414-2420, 2006
PubMed
14) Shayeghi M, Latunde-Dada GO, Oakhill JS, et al. : Identi丘cation of an intestinal heme transporter. Cell 122 : 789-801, 2005
 
15) Sassa S : Why heme needs to be degraded to iron, biliverdin IXalpha, and carbon monoxide? Antioxid Redox Signal 6 : 819-824, 2004
PubMed
16) Novak F, Heyland DK, Avenell A, et al. : Glutamine supPlementation in serious illness : a systematic review of the evidence. Crit Care Med 30 : 2022-2029, 2002
PubMed
17) Wischmeyer PE : Glutamine and heat shock protein expression. Nutrition 18 : 225-228, 2002
PubMed
18) Mates JM, Perez-Gomez C, Nunez de Castro I, et al. : Glutamine and its relationship with intracellular redox status, oxidative stress and cell proliferation/death. Int J Biochem Cell Biol 34 : 439-458, 2002
PubMed
19) Vogt BA, Alam J, Croatt AJ, et al. : Acquired resistance to acute oxidative stress. Possible role of heme oxygenase and ferritin. Lab Invest 72 : 474-483, 1995
PubMed
20) Poss KD, Tonegawa S : Heme oxygenase 1 is required for mammalian iron reutilization. Proc Natl Acad Sci U S A 94 : 10919-10924, 1997
PubMed
21) Ferris CD, Jaffrey SR, Sawa A, et al. : Haem oxygenase-1 prevents cell death by regulating cellular iron. Nat Cell Biol 1 : 152-157, 1999
PubMed
22) Brouard S, Otterbein LE, Anrather J, et al. : Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med 192 : 1015-1026, 2000
PubMed
23) Otterbein LE, Bach FH, Alam J, et al. : Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat Med 6 : 422-428, 2000
PubMed
24) Zhang X, Shan P, Alam J, et al. : Carbon monoxide modulates Fas/Fas ligand, caspases, and Bcl-2 family proteins via the p38 alpha mitogen-activated protein kinase pathway during ischemia-reperfusion lung injury. J Biol Chem 278 : 22061-22070, 2003
 
25) Kim HP, Wang X, Zhang J, et al. : Heat shock protein-70 mediates the cytoprotective effect of carbon monoxide : involvement of p38 beta MAPK and heat shock factor-1. J Immunol 175 : 2622-2629, 2005
PubMed
26) Stocker R, Yamamoto Y, McDonagh AF, et al. : Bilirubin is an antioxidant of possible physiological importance. Science 235 : 1043-1046, 1987
PubMed
27) Baranano DE, Rao M, Ferris CD, et al. : Biliverdin reductase : a major physiologic cytoprotectant. Proc Natl Acad Sci U S A 99 : 16093-16098, 2002
 
28) Djousse L, Rothman KJ, CupPles LA, et al. : Effect of serum albumin and bilirubin on the risk of myocardial infarction (the Framingham Offspring Study). Am J Cardiol 91 : 485-488, 2003
PubMed
29) Reinhart K, Karzai W : Anti-tumor necrosis factor therapy in sepsis : update on clinical trials and lessons learned. Crit Care Med 29 : S121-125, 2001
PubMed
30) Crimi E, Sica V, Williams-Ignarro S, et al. : The role of oxidative stress in adult critical care. Free Radic Biol Med 40 : 398-406, 2006
PubMed
P.83 掲載の参考文献
1) Riedemann NC, Guo RF, Ward PA : The enigma of sepsis. J Clin Invest 112 : 460-467, 2003
PubMed
2) Pol torak A, He X, Smi rnova I, et al. : Defect ive LPS signaling in C 3 H/HeJ and C 57 BL/10 ScCr mice : mutations in Tlr 4 gene. Science. 282 : 2085-2088, 1998
 
3) Hoshino K, Takeuchi O, Kawai T, et al. : Toll-like receptor 4 (TLR 4) -deficient mice are hyporesponsive to lipopolysaccharide : evidence for TLR 4 as the Lps gene product. J Immunol 162 : 3749-3752, 1999
 
4) Nagai Y, Akashi S, Nagafuku M, et al. : Essent ial role of MD-2 in LPS responsiveness and TLR 4 distribution. Nat Immunol 3 : 667-672, 2002
 
5) Tobias PS, Mathison J, Mintz D, et al. : Participat ion of 1 ipopolysaccharide-binding Protein in lipopolysaccharide-dependent macrophage activation. Am J Respir Cell Mol Biol 7 : 239-245, 1992
 
6) Landmann R, Muller B, Zimmer l i W : CD 14, new aspects of ligand and signal diversity. Microbes Infect 2 : 295-304, 2000
 
7) Frey EA, Miller DS, Jahr TG, Soluble CD 14 participates in the response of cells to lipopolysaccharide. J Exp Med 176 : 1665- 1671, 1992
 
8) Landmann R, Link S, Sansano S, et al. : Soluble CD 14 activates monocytic cells independently of lipopolysaccharide. Infect Immun 66 : 2264-2271, 1998
 
9) Ogata M, Matsui T, Ki ta T, et al. : Carrageenan primes leukocytes to enhance lipopolysaccharide-induced tumor necrosis factor alpha production. Infect Immun 67 : 3284-3289, 1999
 
10) Takada K, Ohno N, Yadomae T : Binding of lysozyme to lipopolysaccharide suppresses tumor necrosis factor production in vivo. Infect Immun 62 : 1171-1175, 1994
PubMed
11) Takada K, Ohno N, Yadomae T : Detoxi ficat ion of lipopolysaccharide (LPS) by egg white lysozyme. FEMS Immunol Med Microbiol 9 : 255-263, 1994
 
12) Takada K, Ohno N, Yadomae T : Physicochemical and biological characterizations of complex formation between lipopolysaccharide and lysozyme. J Endotoxin Res 2 : 255-262, 1995 .
 
13) Lehmann V, Freudenberg MA, Galanos C : Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and Dgalactosamine-treated mice. J Exp Med 165 : 657-663, 1987
PubMed
14) Ogata M, Yoshida S, Kamochi M, et al. : Enhancement of lipopolysaccharide-induced tumor necrosis factor production in mice by carrageenan pretreatment. Infect Immun 59 : 679-683, 1991
 
15) Ogata M, Matsumoto T, Koga K, et al. : An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan. Infect Immun 61 : 699-704, 1993
PubMed
16) Bahjat FR, Dharnidharka VR, Fukuzuka K, et al. : Reduced susceptibility of nonobesediabetic mice to TNF-α alpha and D-galactosamine-mediated hepatocellular apoptosis and lethality. J Immunol. 165 : 6559-6567, 2000
 
17) Mimura Y, Sakisaka S, Harada M, et al. : Role of hepatocytes indirect clearance of lipopolysaccharide in rats. Gastroenterology. 109 : 969-9761995
 
18) Tsutsui S, Hirasawa K, Takeda M, et al. : Apoptosis of murine hepatocytes induced by high doses of galactosamine. J Vet Med Sci 59 : 785-790, 1997
PubMed
19) Pan Z, Zhou L, Hetherington CJ, et al. : Hepatocytes contribute to soluble CD 14 production, and CD 14 expression is differentially regulated in hepatocytes and monocytes. J Biol Chem 275 : 36430-36435, 2000
 
20) Bas S, Gauthier BR, Spenato U, et al. : CD 14 is an acute-phase protein. J Immunol, 172 : 4470-4479, 2004
 
21) Liu S, Khemlani LS, Shapi ro RA, et al. : Expression of CD 14 by hepatocytes : upregulation by cytokines during endotoxemia. Infect Immun 66 : 5089-5098, 1998
 
22) Shuto Y, Kataoka M, Higuchi Y, et al. : Roles of CD 14 in LPS-induced 1 iver injury and lethality in mice pretreated with Propionibacterium acnes. Immunol Let t 94 : 47-55, 2004
 
P.87 掲載の参考文献
1) Ohnishi H, Suzuki K, Niho T, et al. : Protective effects of urinary trypsin inhibitor in experimental shock. Jpn J pharmacol 39 : 137-144, 1985
PubMed
2) 小田利通, 鮫島照子, 宮脇武徳, 他 : ヒト尿中トリプシン阻害物質 (MR-20) の抗ショック作用について. 麻酔 33 : 137-142, 1984
Medical*Online
3) 遠藤幸男 : Urinastatinの抗ショック作用をめぐる最近の知見. "ショック1995-1996" 玉熊正悦編. 中山書店, 1995, p84-97
 
4) 玉熊正悦 : 各種ショック患者に対するMR-20の臨床的検討. 救急医学 8 : 619-624, 1984
 
5) 加藤克明, 新居淳, 酒井喜代志 : ヒト尿中トリプシンインヒビター その構造, 物性, および生体内での産生機構を中心として. 医学と薬学 8 : 619-624, 1984
 
6) Balduyck M, Laroui S, Mizon J, et al. : A proteoglycan related to the urinary trypsin inhibitor (UTI) links the two heavy chains of inter-α-trypsin inhibitor. Biol Chem Hoppe Seyler 370 : 329-336, 1986
 
7) Enghild JJ, Thogersen IB, Pizzo SV, et al. : Analysis of inter-α-trypsin inhibitor and a novel trypsin inhibitor, pre-α-trypsin inhibitor, from human plasma. J Biol Chem 264 : 15975-15981, 1989
 
8) 須見洋行, 浜田博喜, 吉田悦男, 他 : 酸安定性トリプシン-プラスミンインヒビター (尿中トリプシンインヒビター関連物質) の構造, 機能および生内分布. 血液と脈管 19 : 545-557, 1988
 
9) Pratt CW, Swaim MW, Pizzo SV : Inflammatory cells degrade inter一α一trypsin inhibitor to liberate urinary protease inhibitors. J Leukoc Biol 45 : 1-9, 1989
 
10) Balduyck M, Piva F, Mizon C, et al. : Human leukocyte elastase (HLE) preferentially cleaves the heavy chain H 2 of inter-α-trypsin inhibitor (1αTI). Biol Chem Hoppe Seyler 374 : 895-901, 1993
 
11) Inoue K, Takano H, Yanagisawa R, et al. : Protective role of urinary trypsin inhibitor in acute lung injury induced by lipopolysaccharide. Exp Biol Med (formerly : P Soc Exp Biol Med) 230 : 281-287, 2005
 
12) Inoue K, Takano H, Shimada A, et al. : Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide. Mol Pharm 67 : 673-680, 2005
 
13) Itoh H, Ide H, Ishikawa N, et al. : Mast cell protease inhibitor, trypstatin, is a fragment of inter-α-trypsin inhibitor light chain. J Biol Chem 269 : 3818-3822, 1994
 
14) 石倉宏恭, 武山直志, 中谷寿男, 他 : エンドトキシンショックにおけるウリナスタチンの抗ショック効果に関する検討-活性化マクロファージのAnandamide産生阻止作用を中心として-. Therapeutic Research 22 : 2411-2416, 2001
 
P.93 掲載の参考文献
1) Muller I, Niethammer D, Bruchelt G : Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity. Int J Mol Med 1 : 491-494, 1998
PubMed
2) Morrison DC, Ulevitch RJ : The effects of bacterial endotoxins on host mediation systems. Am J Pathol 93 : 527-617, 1978
 
3) Morrisgn DC, Ryan JL : Bacterial endotoxins and host immune responses. Adv Immunol 28 : 293-450, 1979
 
4) Oliver FJ, Rubia GD, Rolli V, et al. : Importance of poly (ADP-ribose) polyrnerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 273 : 33533-33539, 1998
 
5) Aubel-Sadron G, Londos-Gagliardi D : Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. Biochimie 66 : 333-352, 1984
PubMed
6) Hartmann A, Agurell E, Beevers C, et al. : Recommendation for conducting the in vivo alkalline comet assay. 4th International Comet Assay Workshop. Mutagenesis 18 : 45-51, 2003
 
7) Tice RR, Agurell E, Anderson D : Single cell gel/Comet assay : Guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 35 : 206-221, 2000
PubMed
8) Vousden KH : Activation of the p 53 tumor suppressor protein. Biochim Biophys Acta 1602 : 47-59, 2002
 
9) Komarov PG, Komarova EA, Roman V : A chemical inhibitor of p 53 that protects mice from the side effects of cancer therapy. Science 285 : 1733-1737, 1999
 
10) Gibson AA, Harwood FG, Tillman DM, et al. : Selective sensitization to DNA-damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type p 53 overexpression. Clin Cancer Res 4 : 145-152, 1998
 
11) Akira S, Takeda K : Toll like receptor signalling. Nature review Immunol 4 : 499-511, 2004
 
12) Giannakakou D, Sackett DL, Ward Y, et al. : p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nat Cell Biol 2 : 709-717, 2000
 
P.98 掲載の参考文献
1) Yu KO, Porcelli SA : The diverse functions of CD 1 d-restricted NKT cells and their potential for immunotherapy. Immunol Lett 100 : 42-55, 2005
 
2) Kobayashi E, Motoki K, Uchida T, et al. : KRN 7000, a novel immunomodulator, and its antitumor activities. Oncol Res 7 : 529-534, 1995
PubMed
3) Kawano T, Cui J, Koezuka Y, et al. : Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc Natl Acad Sci U S A 95 : 5690-5693, 1998
 
4) Giaccone G, Punt CJ, Ando Y, et al. : A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN 7000) in patients with solid tumors. Clin Cancer Res 8 : 3702-3709, 2002
 
5) Miellot A, Zhu R, Diem S, et al. : Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway. Eur J Immunol 35 : 3704-3713, 2005
 
6) Singh AK, Yang JQ, Parekh VV, Wei J, et al. : The natural killer T cell ligand α-galactosylceramide prevents or promotes pristane-in duced lupus in mice. Eur J Immunol 35 : 1143-1154, 2005
 
7) Sharif S, Arreaza GA, Zucker P, et al. : Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat Med 7 : 1057-1062, 2001
 
8) Minagawa S, Ohyama C, Hatakeyama S, et al. : Activation of natural killer T cells by α-galactosylceramide mediates clearance of bacteria in murine urinary tract infection. J Urol 173 : 2171-2174, 2005
 
9) Chackerian A, Alt J, Perera V, et al. : Activation of NKT cells protects mice from tuberculosis. Infect Immun 70 : 6302-6309, 2002
PubMed
10) Nieuwenhuis EE, Matsumoto T, Exley M, et al. : CD 1 d-dependent macrophage-mediated clearance of Pseudomonas aernginosa from lung. Nat Med 8 : 588-593, 2002
 
P.106 掲載の参考文献
1) Cohen J : The immunopathogenesis of sepsis. Nature 420 : 885-891, 2002
PubMed
2) Hancock REW, Diamond G : The role of cationic antimicrobial peptides in innate host defences. Trends Micobiol 8 : 402-410, 2000
 
3) Gennaro R, Zanetti M : Structural features and biological activities of the cathelicidinderived antimicrobial peptides. Biopolymers 55 : 31-49, 2000
PubMed
4) Ramanathan B, Davis E G, Ross C R, et al. : Cathelicidins : microbicidal activity, mechanisms of action, and roles in innate immunity. Microbes Infect 4 : 361-372, 2002
PubMed
5) Gudmundsson GH, Agerberth B : Neutrophil antibacterial peptides, multifunctional effector molecules in the mammalian immune system. J Immunol Methods 232 : 45-54, 1999
PubMed
6) Nagaoka I, Hirota S, Yomogida S, et al. : Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm Res 49 : 73-79, 2000
PubMed
7) Nagaoka I, Hirota S, Niyonsaba F, et al. : Cathelicidin family of antibacterial peptides CAP 18 and CAP 11 inhibit the expression of TNF-α by blocking the binding of LPS to CD 14+ cells. J Immunol 167 : 3329-3338, 2001
 
8) Nagaoka I, Tamura H, Hirata M : An antimicrobial cathelicidin peptide, human CAP 18/LL-37 suppresses neutrophil apoptosis via the activation of FPRL 1 and P2X7. J Immunol 176 : 3044-52, 2006
 
9) Majewska E, Sulowska Z, Baj Z : Spontaneous apoptosis of neutrophils in whole blood and its relation to apoptosis gene proteins. Scand J Immunol 52 : 496-501, 2000
PubMed
10) Vermes I, Haanen C, Reutelingsperger C : Flow cytometry of apoptotic cell death. J Immunol Methods 243 : 167-190, 2000
PubMed
11) Akgul C, Moulding D A, Edwards S W : Molecular control of neutrophil apoptosis. FEBS Lett 487 : 318-322, 2001
PubMed
12) Nolan B, Duffy A, Paquin L, et al. : Mitogenactivated protein kinases signal inhibition of apoptosis in lipopolysaccharide-stimulated neutrophils. Surgery 126 : 406-412, 1999
PubMed
13) Weinmann P, Gaehtgens P, Walzog B : Bcl- Xl- and Bax-α-mediated regulation of apoptosis of human neutrophils via caspase-3. Blood 93 : 3106-3115, 1999
 
14) Mori M, Uchida M, Watanabe T, et al. : Activation of extracellular signal-regulated kinases ERK 1 and ERK 2 induces Bcl-xL up-regulation via inhibition of caspase activities in erythropoietin signaling. J Cell Physiol 195 : 290-297, 2003
PubMed
15) Hengartner M O : The biochemistry of apoptosis. Nature 407 : 770-776, 2000
PubMed
16) Yang D, Chen Q, Schmidt A P, et al. : LL-37, the neutrophil granule- and epithelial cellderived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL 1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192 : 1069-1074, 2000
 
17) Elssner A, Duncan M, Gavrilin M, et al. : A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL-37, induces IL-1βprocessing and release. J Immunol 172 : 4987-4994, 2004
 
18) Bae Y S, Lee H Y, Jo E J, et al. : Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J Immunol 173 : 607-614, 2004
PubMed
19) North R A, Surprenant A : Pharmacology of cloned P2X receptors. Annu Rev Pharmacol Toxicol 40 : 563-580, 2000
PubMed
20) Le Y, Murphy P M, Wang J M : Formylpeptide receptors revised. Trends Immunol 23 : 541-548, 2002
 
21) Hirata M, Shimomura Y, Yoshida M, et al : Characterization of a rabbit cationic protein (CAP 18) with lipopolysaccharide-inhibitory activity. Infect Immun 62 : 1421-1426, 1994
PubMed
22) Ward C, Dransfield I, Chilvers E R, et al. : Pharmacological manipulation of granulocyte apoptosis : potential therapeutic targets. Trends Pharmacol Sci 20 : 503-509, 1999
PubMed
23) Riedemann N C, Guo R F, Ward P A : Novel strategies for the treatment of sepsis. Nat Med 9 : 517-524, 2003
PubMed
24) 長岡功 : 好中球アポトーシスの分子制御. 臨床免疫 43 : 236-242, 2005
 
25) Bowdish D M E, Davidson D J, Hancock R E W : Are-evaluation of the role of host defence peptides in mammalian immunity. Curr Protein Pept Sci 6 : 35-51, 2005
PubMed
26) Sorensen O, Cowland J B, Askaa J, et al. : An ELISA for hCAP 18, the cathelicidin present in human neutrophils and plasma. J Immunol Methods 206 : 53-59, 1997
PubMed
27) Kirikae T, Hirata M, Yamasu H, et al. : Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP 18) -derived peptide against murine endotoxemia. Infect Immun 66 : 1861-1868, 1998
PubMed
28) Bowdish D M E, Davidson D J, Lau Y E, et al. : Impact of LL-37 on anti-infective immunity. J Leukoc Biol 77 : 451-459, 2005
PubMed
P.111 掲載の参考文献
1) Lehrer RI, Ganz T, Selsted ME, et al. : Neutrophils and host defense. Ann Intern Med 109 : 127-142, 1988
PubMed
2) Zanetti M, Gennaro R, Romeo D. Cathelicidins : a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 374 : 1-5, 1995
 
3) Yomogida S, Nagaoka I, Yamashita T : Purification of the 11- and 5-kDa antibacterial polypeptides from guinea pig neutrophils. Arch Biochem Biophys 328 : 219-226, 1996
PubMed
4) Nagaoka I, Tsutsumi-Ishii Y, Yomogida S, et al. : Isolation of cDNA encoding guinea pig neutrophil cationic antibacterial polypeptide of 11 kDa (CAP 11) and evaluation of CAP 11 mRNA expression during neutrophil maturation. J Biol Chem 272 : 22742-22750, 1997
 
5) Nagaoka I, Hirota S, Yomogida S, et al. : Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm Res 49 : 73-79, 2000
PubMed
6) Nagaoka I, Hirota S, Niyonsaba F, et al. : Cathelicidin family of antibacterial peptides CAP 18 and CAP 11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD 14 (+) cells. J Immunol 167 : 3329-3338, 2001
 
7) Varga K, Wagner JA, Bridgen DT, et al. : Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. Faseb J 12 : 1035-1044, 1998
PubMed
8) Wang Y, Liu Y, Sarker KP, et al. : Polymyxin B binds to anandamide and inhibits its cytotoxic effect. FEBS Lett 470 : 151-155, 2000
 
9) Liu J, Batkai S, Pacher P, et al. : Lipopolysaccharide induces anandamide synthesis in macrophages via CD 14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem 278 : 45034-45039, 2003
 
10) Malinowska B, Kwolek G, Gothert M : Anandamide and methanandamide induce both vanilloid VR 1 -and cannabinoid CB 1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 364 : 562-569, 2001
 
11) Ueda N, Okamoto Y, Morishita J : N-acylphosphatidylethanolamine-hydrolyzing phospholipase D : a novel enzyme of the betalactamase fold family releasing anandamide and other N-acylethanolamines. Life Sci 77 : 1750-1758, 2005
PubMed
12) Ueda N, Yamamoto S : Anandamide amidohydrolase (fatty acid amide hydrolase). Prostaglandins Other Lipid Mediat 61 : 19-28, 2000
 
13) Kwolek G, Zakrzeska A, Kozlowska H, et al. : [Influence of anandamide, the endogenous agonist of cannabinoid receptors on the circulatory system]. Postepy Hig Med Dosw (Online) 59 : 208-218, 2005
PubMed
14) Batkai S, Pacher P, Jarai Z, et al. : Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB 1 or CB 2 receptors. Am J Physiol Heart Circ Physiol 287 : H595-600, 2004
 
15) Bligh EG, Dyer WJ : A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37 : 911-917, 1959
PubMed
P.118 掲載の参考文献
1) Hancock RE, Diamond G : The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 8 : 402-410, 2000
PubMed
2) Gennaro R, Zanetti M : Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. Biopolymers 55 : 31-49, 2000
PubMed
3) Ramanathan B, Davis EG, Ross CR, et al. : Cathelicidins : microbicidal activity, mechanisms of action, and roles in innate immunity. Microbes Infect 4 : 361-372, 2002
PubMed
4) Travis SM, Anderson NN, Forsyth WR, et al. : Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 68 : 2748-2755, 2000
PubMed
5) Zanetti M, Gennaro R, Romeo D. Cathelicidins : a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 374 : 1-5, 1995
 
6) Yomogida S, Nagaoka I, Yamashita T : Purification of the 11-and 5-kDa antibacterial polypeptides from guinea pig neutrophils, Arch Biochem Biophys 328 : 219-226, 1996
PubMed
7) Nagaoka I, Tsutsumi-lshii Y, Yomogida S, et al. : Isolation of cDNA encoding guinea pig neutrophil cationic antibacterial polypeptide of 11 kDa (CAP 11) and evaluation of CAP 11 mRNA expression during neutrophil maturation. J Biol Chem 272 : 22742-22750, 1997
 
8) Nagaoka I, Hirota S, Yomogida S, et al. : Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm Res 49 : 73-79, 2000
PubMed
9) Nagaoka I, Hirota S, Niyonsaba F, et al. : Cathelicidin family of antibacterial peptides CAP 18 and CAP 11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD 14 (+) cells. J Immunol 167 : 3329-3338, 2001
 
10) Okuda D, Yomogida S, Tamura H, et al. : Determination of the antibacterial and LPS-neutralizing regions of guinea pig neutrophil cathelicidin peptide CAP 11. Antimicrob Agents Chemother 50 : 2602-2607, 2006
 
11) Seydel U, Schromm AB, Blunck R, et al. : Chemical structure, molecular conformation, and bioactivity of endotoxins. Chem Immunol 74 : 5-24, 2000
PubMed
12) Lehrer RI, Lichtenstein AK, Ganz T : Defensins : antimicrobial and cytotoxic peptides of mammalian cells. Annu Rev Immunol 11 : 105-128, 1993
PubMed
13) Scott MG, Vreugdenhil AC, Buurman WA, et al. : Cutting edge : cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J Immunol 164 : 549-553, 2000
PubMed
14) Larrick JW, Hirata M, Shimomoura Y, et al. : Antimicrobial activity of rabbit CAP 18-derived peptides. Antimicrob Agents Chemother 37 : 2534-2539, 1993
PubMed
15) Larrick JW, Hirata M, Zhong J, et al. : Antimicrobial activity of human CAP 18 peptides. Immunotechnology 1 : 65-72, 1995
 
16) Hirata M, Shimomura Y, Yoshida M, et al. : Characterization of a rabbit cationic protein (CAP 18) with lipopolysaccharide-inhibitory activity. Infect Immun 62 : 1421-1426, 1994
PubMed
17) Nagaoka I, Hirota S, Niyonsaba F, et al. : Augmentation of the lipopolysaccharideneutralizing activities of human cathelicidin CAP 18/LL-37-derived antibacterial peptide by replacement with hydrophobic and cationic amino acid residues. Clin Diagn Lab Immunol 9 : 972-982, 2003
 
18) Aderem A, Ulevitch RJ : Toll-like receptors in the induction of the innate immune response. Nature 406 : 782-787, 2000
PubMed
19) Fenton MJ, Golenbock DT : LPS-binding proteins and receptors. J Leukoc Biol 64 : 25-32, 1998
PubMed
20) Morrison DC, Danner RL, Dinarello CA, et al. : Bacterial endotoxins and pathogenesis of Gram-negative infections : current status and future direction. J Endotoxin Res 1 : 71-83, 1994
 
21) Wright SD, Ramos RA, Tobias PS, et al. : CD 14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249 : 1431-1433, 1990
 
P.128 掲載の参考文献
1) Rietschel ET, Kirikae T, Schade FU, et al. : Bacterial endotoxin : molecular relationships of structure to activity and function. FASEB J 8 : 217-225, 1994
PubMed
2) Cohen J : The immunopathogenesis of sepsis. Nature 420 : 885-891, 2002
PubMed
3) Labeta MO, Durieux JJ, Spagnoli G, et al. : CD 14 and tolerance to Iipopolysaccharide, biochemical and functional analysis. Immunology 80 : 415-423, 1993
 
4) Suhletter J, Heine H, Ulmer AJ, et al : Molecular mechanisms of endotoxin activity. Arch Microbiol 164 : 383-389, 1995
 
5) Zanetti G, Heumann D, Gerain J, et al. : Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. J Immunol 148 : 1890-1897, 1992
PubMed
6) Van Zee KJ, DeForge LE, Fischer E, et al. : IL-8 in septic shock, endotoxemia, and after IL-1 administration. J Immunol 146 : 3478-3482, 1991
PubMed
7) Riedemann NC, Guo RF, Ward PT : The enigma of sepsis. J Clin Invest 112 : 460-467, 2003
 
8) Hotchkiss RS, Karl IE : The pathophysiology and treatment of sepsis. N Engl J Med 348 : 138-150, 2003
PubMed
9) Rustici A, Velucchi M, Faggiono R, et al. : Molecular mapping and detoxification of the lipid A binding site by synthetic peptides. Science 259 : 361-365, 1993
 
10) Elass-Rochard E, Legrand D, Salmon V, et al. : Lactoferrin inhibits the endotoxin interaction with CD 14 by competition with the lipopolysaccharide-binding protein. Infect Immunol 66 : 486-491, 1998
 
11) Dankesreiter S, Hoess A, Schneider-Mergener J, et al. : Synthetic endotoxin-binding Peptides block endotoxin-triggered TNF-α production by macrophages in vitro and in vivo and prevent endotxin-mediated toxic shock. J Immunol 164 : 4804-4811, 2000
 
12) Hirata M, Zhong J, Wright SC, et al. : Structure and functions of endotxin-binding peptides derived from CAP 18. Prog Clin Biol Res 392 : 317-326, 1995
 
13) Turner J, Cho Y, Dinh NN, et al. : Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42 : 2206-2214, 1998
PubMed
14) Smith GP : Filamentous fusion phage : novel expression vectors that display colned antagonist on the virion surface. Science 14 228 : 1315-1317, 1985
 
15) 鈴木政嗣, 松本めぐみ, 落合雅樹, 他 : ファージディスプレイ法によるエンドトキシン研究の新戦略. "エンドトキシン研究 7-可能性を求めて-" 日本エンドトキシン研究会 遠藤重厚, 小玉正智, 横地高志, 谷徹, 編集. 医学図書出版, 2004, pp 65-72
 
16) Noda K, Yamasaki R, Hirooka Y, et al. : Selection of peptides that bind to the core oligosaccharide of R-from LPS from a phagedisplayed heptapeptide library. FEMS Microbiol Lett 205 : 349-354, 2000
 
17) Zhu Y, Ho B, Ding JL : Sequence and structural diversity in endotoxin-binding dodecapeptides. Biochim Biophys Acta. 1611 : 234-242, 2003
PubMed
18) Guo X, Chen RR : An improved phage display procedure for identification of lipopolysaccharide-binding peptides. Biotechnol Prog 22 : 601-604, 2006
 
19) Harris NS, Feinstein R : The LAL-beads assay for endotoxin. Prog Clin Biol Res. 29 : 265-274, 1979
 
20) Yang H, Daun JM, Rose JR, et al. : Examination of chlorpromazine and other amphipathic drugs on the activity of lipopolysaccharide, E5564 and E5531. J Endotoxin Res 6 : 447-452, 2000
PubMed
21) Mullarkey M, Rose JR, Bristol J, et al. : Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J pharmacol Exp Ther 304 : 1093-1102, 2003
PubMed
22) Savov JD, Brass DM, Lawson BL, et al. : Toll-like receptor 4 antagonist (E 5564) prevents the chronic airway response to inhaled lipopolysaccharide. Am J physiol Lung Cell Mol Physiol 289 : 329-337, 2005
 
23) Lynn M, Wong YN, Wheeler JL, et al. : Extended in vivo pharmacodynamic activity of E 5564 in normal volunteers with experimental endotoxemia. J Pharmacol Exp Ther 308 : 175-181, 2004
PubMed
24) Ii M, Matsunaga N, Hazeki K, et al. : A novel cyclohexene derivative, ethyl (6 R) -6- [N- (2-Chloro-4-fuluorophenyl) sulfamoyl］cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol Pharmacol 69 : 1288-1298, 2006
 
P.134 掲載の参考文献
1) Yatsuyanagi J, Saito S, Sato H, et al. : Characterization of enteropathogenic and enteroaggregative Escherichia coli isolated from diarrheal outbreaks. J Clin Microbiol 40 : 294-297, 2002
PubMed
2) 木村晋亮, 小松崎明子, 佐々木富子, 他 : 散発下痢症患者および健常者から分離された糞便由来大腸菌O抗原血清型の比較と地域差. 感染症誌 73 : 53-61, 1999
 
3) Chart H, Rowe B : Improved detection of infection by Escherichia coli O 157 in patients with haemolytic uraemic syndrome by means of IgA class antibodies to lipopolysaccharide. J Infect 24 : 257-261, 1992
 
4) Bitzan M, Ludwig K, Klent M, et al. : The role of Escherichia coli O 157 infections in classical (enteropathic) haemolytic uraemic syndrome : results of a central European, multicentre study. Epidemiol Infect 110 : 183-196, 1993
 
5) Barrett TJ, Green JH, Griffin PM, et al. : Enzyme-linked immunosorbent assays for detecting antibodies to Shiga-like toxin-I, Shiga-like toxin-II, and Escherichia coli O157 : H7 lipopolysaccharide in human serum. Curr Microbiol 23 : 189-195, 1991
 
6) Greatorex JS, Thome GM : Humoral immune response to Shiga-like toxins and Escherichia coli O157 lipopolysaccharide in Hemolyticuremic syndrome patients and healthy subjects. J Clin Microbiol 32 : 1172-1178, 1991
 
7) Banatvala N, Magnano AR, Cartter ML, et al. : Meat grinders and molecular epidemiology : two supermarket outbreaks of Escherichia coli O 157 : H7 infection. J Infect Dis 173 : 480-483, 1996
 
8) Caprioli A, Luggi I, Rosmini F : Hemolyticuremic syndrome and Vero cytotoxin-producing Escherichia coli infection in Italy. J Infect Dis 166 : 154-158, 1992
PubMed
9) Siddons CA, Chapman PA : Detection of serum and faecal antibodies in haemorrhagic colitis caused by Escherichin coli O 157. J Med Microbiol 39 : 408-415, 1993
 
10) Yamada S, Kai A, Kudoh Y : Serodiagnosis by passive haemagglutination test and verocytotoxin enzyme-linked immunosrbent assay of toxin-producing Escherichia coli infections in patients with hemolytic uremic syndrome. J Clin Mirobiol 32 : 955-959, 1994
 
11) 小野智子, 高田真人, 前田俊郎, 他 : ラッテクス凝集法を用いた血清中の腸管出血性大腸菌O157 LPS抗体検出キットの開発. 臨床検査 42 : 945-947, 1998
 
12) Thiurumalapura NR, Morton RJ, Ramachandra A, et al. : Lipopolysaccharide microarrays for the detection of antibodies. J Immunol Meth 298 : 73-81, 2005
 
13) Wilson JB, Clarke RC, Renwick SA, et al. : Vero cytotoxigenic Eschen'chia coli infection in dairy farm families. J Infect Dis 174 : 1021-1027, 1996
 
14) Chart H, Cheasty T, Rowe B : Serological identification of infection with Verocytotoxinproducing Escherichia coli. Lett Appl Microbiol 23 : 322-324, 1996
PubMed
15) Chart H, Jenkins C : The serodiagnosis of infections caused by verocytotoxin-producing Escherichia coli. J Appl Microbiol 86 : 731-740, 1999
PubMed
16) 厚生省病原性大腸菌O157対策本部 : 堺市学童集団下痢症の原因究明について (調査結果まとめ) 1996年9月
 
P.140 掲載の参考文献
1) Arron JR, and Choi Y : Bone versus immune system. Nature 408 : 535-536, 2000
PubMed
2) Ray N, Kuwahara M, Takada Y, et al. : c-Fos suppresses systemic inflammatory response to endotoxin. Int Immunol 18 : 671-677, 2006
PubMed
3) Wong BR, Josien R, Lee SY, et al. : TRANCE (tumor necrosis factor [TNF］-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is adendritic cell-specific survival factor. J Exp Med 186 : 2075-2080, 1997
 
4) Anderson DM, Maraskovsky E, Billingsley WL, et al. : A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 : 175-179, 1997
PubMed
5) Yasuda H, Shima N, Nakagawa N, et al. : Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95 : 3597-3602, 1998
PubMed
6) Lacey DL, Timms E, Tan HL, et al. : Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 : 165-176, 1998
PubMed
7) Kong YY, Yoshida H, Sarosi I, et al. : OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 : 315-323, 1999
PubMed
8) Mizuno A, Kanno T, Hoshi M, et al. : Transgenic mice overexpressing soluble osteoclast differentiation factor (sODF) exhibit severe osteoporosis. J Bone Miner Metab 20 : 337-344, 2002
 
9) Matsuo K, and Ray N : Osteoclasts, mononuclear phagocytes, and c-Fos : new insight into osteoimmunology. Keio J Med 53 : 78-84, 2004
 
10) Grigoriadis AE, Wang ZQ, Cecchini MG, et al. : c-Fos : a key regulator of osteoclastmacrophage lineage determination and bone remodeling. Science 266 : 443-448, 1994
PubMed
11) Matsuo K, Owens JM, Tonko M, et al. : Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation. Nat Genet 24 : 184-187, 2000
PubMed
12) Maruyama K, Takada Y, Ray N, et al. : Receptor Activator of NF-κB Ligand and Osteoprotegerin Regulate Proinflammatory Cytokine Production in Mice. J Immunol 177 : 3799-3805, 2006
 
P.150 掲載の参考文献
1) Takeda K, Kaisho T, Akira S : Toll-like receptors. Annu Rev Immunol 21 : 335-376, 2001
PubMed
2) Meng G, Rutz M, Schiemann M, et al. : Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J Clin Invest 113 : 1473, 2004
PubMed
3) Mizel SB, West AP, Hangton RR : Identification of a sequence in human toll-like receptor 5 required for the binding of Gramnegative flagellin. J Biol Chem 278 : 23624-23629, 2004
 
4) Rutz M, Metzger J, Gellert T, Luppa P, et al. : Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence-and pH-dependent manner. Eur J Immunol 34 : 2541, 2004
 
5) Lis H. and Sharon N : Protein glycosylation. Structural and functional aspects. Eur J Biochem 218 : 1-27, 1993
PubMed
6) Saxon E, Bertozzi CR : Chemical and Biological strategies for engineering cell surface glycosylation. Annu Rev Cell Dev Biol 17 : 1-23, 2001
PubMed
7) Choe J, Kelker MS, Wilson IA : Crystal structure of human toll-like receptor 3 (TLR 3) ectodomain. Science 309 : 581-585, 2005
 
8) Weber ANR, Morse MA, Gay NJ : Four N-linked glycosylation sites in human Toll-like receptor 2 cooperate to direct efficient biosynthesis and secretion. J Biol Chem 279 : 34589, 2004
PubMed
9) Ohnishi T, Muroi M, Tanamoto K : N-linked glycosylation at Asn (26) and Asn (114) of human MD-2 are required for toll-like receptor 4-mediated activation of NF-kappa B by lipopolysaccharide. J Immunol 167 : 3354-3359, 2001
PubMed
10) da Silva Correia, J, Ulevitch RJ : MD-2 and TLR 4 N-linked glycosylations are important for a functional lipopolysaccaride receptor. J Biol Chem 277 : 1845-1854, 2002
 
11) 0hnishi T, Muroi M, Tanamoto K : MD-2 is necessary for the toll-like receptor 4 protein to undergo glycosylation essential for its translocation to the cell surface. Clin Diagn Lab Immunol 10 : 405-410, 2003
 
12) Okusawa T, Fujita M, Shibata K, et al. : Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by Toll-like receptors 2 and 6. Infect Immun 72 : 1657, 2004
PubMed
13) Fujita M, Into T, Shibata K, et al. : Involvement of leucine residues at positions 107, 112, and 115 in a leucine-rich repeat motif of human Toll-like receptor 2 in the recognition of diacylated lipoproteins and lipopeptides and Staphylococcus aureus peptidoglycans. J Immunol 171 : 3675, 2003
 
14) Braun V, Wu HC : Lipoproteins, structure, function, biosynthesis and model for protein export, In : Ghuysen JM, Hakenbeck R, editors. New comprehensive biochemistry. : bacterial cell wall. Elsevier Science, Amsterdam, 27 : 319, 1994
 
15) Muhlradt PF, Meyer H, Jansen R : Identification of S- (2, 3-dihydroxypropyl) cysteine in a macrophage-activating lipopeptide from Mycoplasmas fermentans. Biochemistry 35 : 7781, 1996
 
16) Shibata K, Hasebe A, Sasaki T, et al. : Mycoplasma salivarium induces interleukin-6 and interleukin-8 in human gingival fibroblasts. FEMS. Immunol Med Microbiol 19 : 275, 1998
 
17) Dong L, Shibata K, Sawa Y, et al. : Transcriptional activation of mRNA of intercellular adhesion molecule 1 and induction of its cell surface expression in normal human gingival fibroblasts by Mycoplasma salivarium and Mycoplasma fermentans. Infect Immun 67 : 3061, 1999
PubMed
18) Shibata K, Hasebe A, Into T, et al. : The N-terminal lipopeptide of a 44 kDa membranebound lipoprotein of Mycoplasma salivarium is responsible for the expression of intercellular adhesion molecule-1 on the cell surface of normal human gingival fibroblasts. J Immunol 165 : 6538, 2000
 
19) Meng G, Grabiec A, Kirschning CJ, et al. : Cellular recognition of tri-/di-palmitoylated peptides is independent from a domain encompassing the N-terminal seven leucine-rich repeat (LRR) /LRR-like motifs of TLR 2. J Biol Chem 278 : 39822, 2003
 
20) Sandor F, Latz E, Golenbock DT, et al. : Importance of extra-and intracellular domains of TLR 1 and TLR 2 in NFkappa B signaling. J Cell Biol 162 : 1099-1110, 2003
PubMed
21) Uehori J, Matsumoto M, Akira S, et al. : Simultaneous blocking of human Toll-like receptor 2 and 4 surpresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guerin peptidoglycan. Infect Immun 71 : 4238-4249, 2003
 
22) Buwitt-Beckmann U, Heine H, Ulmer AJ, et al. : Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol 35 : 282, 2005
PubMed
23) Buwitt-Beckmann U, Heine H, Ulmer AJ, et al. : TLR 1-and TLR 6-independent recognition of bacterial lipopeptides. J Biol Chem In press 2006
 
24) Kobe B, Deisenhofer J : Proteins with leucinerich repeats Curr. Opi Struct Biol 5 : 409, 1995
 
25) Bell JK, Mullen GED, Segal DM, et al. : Leucine-rich repeats and pathogen recognition in Toll-like receptors. Trends Immunol 24 : 528, 2003
PubMed
26) Alexopoulou L, Holt AC, Medzhitov R, et al. : Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413 : 732-738, 2001
PubMed
27) Bouteiller O, Merck E, Caux C, et al. : Recognition of double-stranded RNA by human Toll-like receptor 3 and downstream receptor signaling requires multimerization and acidic pH. J Biol Chem 280 : 38133-38145, 2005
PubMed
28) Kim J-I, Lee CJ, Lee J-O, et al. : Crystal Structure of CD 14 and Its Implications for Lipopolysaccharide Signaling. J Biol Chem 280 : 11347, 2005
 
29) Omueti KO, Beyer JM, Tapping RI, et al. : Domain exchange between human toll-like receptor 1 and 6 reveals a region required for lipopeptide discrimination. J Biol Chem 280 : 36616-36625, 2005
PubMed
30) Gabiec A, Meng G, Kirschning CJ, et al. : Human but not murine toll-like receptor 2 discriminates between tri-palmitoylated and tri-lauroylated peptides. J Biol Chem 279 : 48004-48012, 2004
 
P.157 掲載の参考文献
1) Fujihara M, Muroi M, Tanamoto K, et al. : Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide : roles of the receptor complex. Pharmacol Ther 100 : 171-194, 2003
PubMed
2) Miyake K : Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol 12 : 186-192, 2004
PubMed
3) Gioannini TL, Teghanemt A, Zhang D, et al. : Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci USA 101 : 4186-4191, 2004
PubMed
4) Nagai Y, Akashi S, Nagafuku M, et al. : Essential role of MD-2 in LPS responsiveness and TLR 4 distribution. Nat Immunol 3 : 667-672, 2002
 
5) da Silva CJ, Ulevitch RJ : MD-2 and TLR 4 N-linked glycosylations are important for a functional lipopolysaccharide receptor. J Biol Chem 277 : 1845-1854, 2002
 
6) Ohnishi T, Muroi M, Tanamoto K : MD-2 is necessary for the Toll-like receptor 4 protein to undergo glycosylation essential for its translocation to the cell surface. Clin Diagn Lab Immunol 10 : 405-410, 2003
 
7) Tanamoto K, Azumi S : Salmonella-type heptaacylated lipid A is inactive and acts as an antagonist of lipopolysaccharide action on human line cells. J. Immunol. 164 : 3149-3156, 2000
 
8) Means TK, Golenbock DT, Fenton MJ : The biology of Toll-like receptors. Cytokine Growth Factor Rev 11 : 219-232, 2000
PubMed
9) Poltorak A, Ricciardi-Castagnoli P, Citterio S, et al. : Physical contact between lipopolysaccharide and Toll-like receptor 4 revealed by genetic complementation. Proc Natl Acad Sci U. S. A. 97 : 2163-2167, 2000
PubMed
10) Lien E, Means TK, Heine H, et al. : Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J Clin Invest 105 : 497-504, 2000
PubMed
11) Akashi S, Nagai Y, Ogata H, et al. : Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition Int Immunol 13 : 1595-1599, 2001
PubMed
12) Muroi M, Ohnishi T, Tanamoto K : MD-2, a novel accessory molecule, is involved in species-specific actions of Salmonella lipid A. Infect Immun 70 : 3546-3550, 2002
PubMed
13) Hajjar AM, Ernst RK, Tsai JH, et al. : Human Toll-like receptor 4 recognizes hostspecific LPS modifications. Nat Immunol 3 : 354-359, 2002
PubMed
14) Muroi M, Tanamoto KI : Structural regions of MD-2 that determine the agonist-antagonist activity of lipid IVa. J Biol Chem 281 : 5484-5491, 2005
 
15) Viriyakosol S, Tobias PS, Kitchens RL, et al. : MD-2 Binds to Bacterial Lipopolysaccharide. J Biol Chem 276 : 38044-38051, 2001
PubMed
16) Visintin A, Latz E, Monks BG, et al. : Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem 278 : 48313-48320, 2003
 
17) Re F, Strominger JL : Separate functional domains of human MD-2 mediate Toll-like receptor 4-binding and lipopolysaccharide responsiveness. J Immunol 171 : 5272-5276, 2003
PubMed
18) Mancek M, Pristovsek P, Jerala R : Identification of LPS-binding peptide fragment of MD-2, a Toll-receptor accessory protein. Biochem Biophys Res Commun 292 : 880-885, 2002
PubMed
19) Kawasaki K, Nogawa H, Nishijima M : Identification of mouse MD-2 residues important for forming the cell surface TLR 4-MD-2 complex recognized by anti-TLR 4-MD-2 antibodies, and for conferring LPS and taxol responsiveness on mouse TLR 4 by alaninescanning mutagenesis. J Immunol 170 : 413-420, 2003
PubMed
20) Gangloff M, Gay NJ : MD-2 : the Toll 'gatekeeper' in endotoxin signalling. Trends Biochem Sci 29 : 294-300, 2004
PubMed
21) Gruber A, Mancek M, Wagner H, et al. : Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition. J Biol Chem 279 : 28475-28482, 2004
PubMed
P.163 掲載の参考文献
1) Akira S, Takeda K : Toll-like receptor signalling. Nat Rev Immunol 4 : 499-511, 2004
PubMed
2) Takada H, Kotani S : Immunopharmacological activities of synthetic muramylpeptides. In "Immunology of the Bacterial Cell Envelope", eds Stewart-Tull DES, Davies M, John Wiley & Sons, Chichester, 1985, p 119-152
 
3) Takada H, Kotani S : Muramyl dipeptide and derivatives. In "The Theory and Practical Application of Adjuvants", ed Stewart-Tull DES, John Wiley & Sons, Chichester, 1995, p171-202
 
4) Adam A : Muramylpeptides and analogues. In "Synthetic Adjuvants", John Wiley & Sons, New York, 1985, p 1-58
 
5) Goto T, Aoki H : The immunomodulatory activities of acylpeptides. In "Immunostimulants : Now and Tomorrow", eds Azuma I, Jolles G, 1987, p 99-108
 
6) Yoshimura A, Lien E, Ingalls RR, et al. : Recognition of Gramっositive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 163 : 1-5, 1999
 
7) Yang S, Tamai R, Akashi S, et al. : Synergistic effect of muramyldipeptide with lipopolysaccharide or Iipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture. Infect Immun 69 : 2045-2053, 2001
PubMed
8) Vidal VF, Casteran N, Riendeau CJ, et al. : Macrophage stimulation with murabutide, an HIV-suppressive muramyl peptide derivative, SeleCtiVely aCtivateS extraCellular Signalregulated kinases 1 and 2, C/EBPβ and STAT 1 : role of CD 14 and Toll-like receptors 2 and 4. Eur J Immunol 31 : 1962-1971, 2001
 
9) Takada H, Yokoyama S, Yang S : Enhancement of endotoxin activity by muramyldipeptide. J Endotoxin Res 8 : 337-342, 2002
PubMed
10) Inohara N, Ogura Y, Fontalba, et al. : Host recognition of bacterial muramyl dipeptide mediated through NOD 2. J Biol Chem 278 : 5509-5512, 2003
 
11) Girardin SE, Boneca IG, Viala J, et al. : Nod 2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278 : 8869-8872, 2003
 
12) Girardin SE, Boneca IG, Carneiro LAM, et al. : Nod l detects a unique muropeptide from Gram-negative bacterial peptidoglycan. Science 300 : 1584-1587, 2003
 
13) Chamaillard M, Hashimoto M, Horie Y, et al. : An essential role for NOD l in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat Immunol 4 : 702-707, 2003
 
14) Sugawara Y, Uehara A, Fujimoto Y, et al. : Toll-like receptors, NOD 1, and NOD 2 in oral epithelial cells. J Dent Res 85 : 524-529, 2006
 
15) Uehara A, Sugawara S, Tamai R, et al. : Contrasting responses of human gingival and colonic epithelial cells to lipopolysaccharides, lipoteichoic acids and peptidoglycans in the presence of soluble CD 14. Med Microbiol Immunol 189 : 185-192, 2001
 
16) Uehara A, Sugawara Y, Kurata S, et al. : Chemically synthesized pathogen-associated molecular patterns increase the expression of peptidoglycan recognition proteins via Toll-like receptors, NOD 1 and NOD 2 in human oral epithelial cells. Cell Microbiol 7 : 675-686, 2005
PubMed
17) Dziarski R : Peptidoglycan recognition proteins (PGRPs). Mol Immnol 40 : 877-886, 2004
PubMed
18) Uehara A, Sugawara S, Takada H : Priming of human oral epithelial cells by interferon-γ to secrete cytokines in response to lipopolysaccharides, lipoteichoic acids and peptidoglycans. J Med Microbiol 51 : 626-634, 2002
 
19) Uehara A, Yang S, Fujimoto Y, et al. : Muramyldipeptide and diaminopimelic acidcontaining desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD 2-and NOD 1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol 7 : 53-61, 2005
 
20) Kobayashi KS, Chamaillard M, Ogura Y, et al. : Nod 2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307 : 731-734, 2005
 
P.171 掲載の参考文献
1) Imoto M, Kusumoto S, Shiba T, et al. : Chemical structure of E. coli lipid A : linkage site of acyl groups in the disaccharide backbone. Tetrahedron Lett 24 : 4017-4020, 1983
 
2) Lehmann V : Isolation, purification and prop erties of an intermediate in 3-deoxy-D-mannooctulosonic acid--lipid A biosynthesis. Eur J Biochem 75 : 257-266, 1977
 
3) Krauss JH, Seydel U, Weckesser J, et al. : Structural analysis of the nontoxic lipid A of Rhodobacter capsulatzas 37 b 4. Eur J Biochem 180 : 519-526, 1989
 
4) Loppnow H, Libby P, Freudenberg M, et al. : Cytokine induction by lipopolysaccharide (LPS) corresponds to lethal toxicity and is inhibited by nontoxic Rhodobacter capsulatzts LPS. Infect Immun 58 : 3743-3750, 1990
PubMed
5) Qureshi N, Honovich Jp, Hara H, et al. : Location of fatty acids in lipid A obtained from lipopolysaccharide of Rhodopseudomonas Sphaeroides ATCC 17023. J Biol Chem 263 : 5502-5504, 1988
PubMed
6) Takayama K, Qureshi N, Beutler B, et al. : Diphosphoryl lipid A from Rhodopseudomonas Sphaeroides ATCC 17023 blocks induction of cachectin in macrophages by lipopolysaccharide. Infect Immun 57 : 1336-1338, 1989
PubMed
7) Rose JR, Christ WJ, Bristol JR, et al. : Agonistic and antagonistic activities of bacterially derived Rhodobacter Sphaeroides lipid A : comparison with activities of synthetic material of the proposed structure and analogs. Infect Immun 63 : 833-839, 1995
PubMed
8) Christ WJ, Asano O, Robidoux AL, et al. : E5531, a pure endotoxin antagonist of high potency. Science 268 : 80-83, 1995
PubMed
9) Rossignol DP, Hawkins LD, Christ WJ, et al. : Synthetic Endotoxin Antagonists. In "Endotoxin in Health and Disease", eds. Brade H, Opal SM, Vogel SN, Morrison DC, 1999, p 699-717
 
10) Conrad RC, Kist M, Schlecht S, et al. : Extraction and biochemical analyses of Helicobacter pylori lipopolysaccharide. Curr Microbiol 28 : 165-169, 1992
 
11) Moran AP, Helander IM, Kosunen TU : Compositional analysis of Helicobacter pylori rough-form lipopolysaccharides. J Bacteriol 174 : 1370-1377, 1992
PubMed
12) Suda Y, Ogawa T, Kashihara W, et al. : Chemical structure of lipid A from Helicobacter Pylori strain 206-1 lipopolysaccharide. J Biochem (Tokyo) 121 : 1129-1133, 1997
PubMed
13) Moran AP, Lindner B, Walsh EJ : Structural characterization of the lipid A component of Helicobacter pylori rough-and smooth-form lipopolysaccharides. J Bacteriol 179 : 6453-6463, 1997
PubMed
14) Suda Y, Kim YM, Ogawa T, et al. : Chemical structure and biological activity of a lipid A component from Helicobacter pylori strain 206. JEndotoxin Res 7 : 95-104, 2001
PubMed
15) Ogawa T, Suda Y, Kashihara W, et al. : Immunobiological activities of chemically defined lipid A from Helicobacter pylori LPS in comparison with Porphyromonas gingivalis lipid A and Escherichia coli-type synthetic lipid A (compound 506). Vaccine 15 : 1598-1605, 1997
PubMed
16) Lepper PM, Triantafilou M, Schumann C, et al. : Lipopolysaccharides from Helicobacter pylori can act as antagonists for Toll-like receptor 4. Cell Microbiol 7 : 519-528, 2005
PubMed
17) Sakai Y, Oikawa M, Yoshizaki H, et al. : Synthesis of Helicobacter pylori lipid A and its analogue using p- (trifluoromethyl) benzyl protecting group. Tetrahedron Lett 41 : 6843-6847, 2000
 
18) Ogawa T, Asai Y, Sakai Y, et al. : Endotoxic and immunobiological activities of a chemically synthesized lipid A of Helicobacter pylori strain 206-1. FEMS Immunol Med Microbiol 36 : 1-7, 2003
PubMed
19) Akamatsu M, Fujimoto Y, Kataoka M, et al. : Synthesis of lipid A monosaccharide analogues containing acidic amino acid : exploring the structural basis for the endotoxic and antagonistic activities. Biomol Med Chem 14 : 6759-6777, 2006
 

書評

最近チェックした商品履歴

Loading...